The Board of the company currently consists of one executive member and five non-executive members, each of whom is considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance valuable experience of Idorsia’s business with fresh perspectives.
The Idorsia Executive Committee
Date of birth: 3 April 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Founder and CEO of Actelion 1999-2017. Joined Idorsia as CEO when the company was established in June 2017.
Date of birth: 27 December 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology. Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd. Founder and Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion, 1997–2009. Chief Scientific Officer of Actelion 2009-2017. Joined Idorsia as Chief Scientific Officer when the company was established in June 2017.
Officer of the Legion of Honour
Date of birth: 19 November 1956
Education: MD, pulmonologist and PhD in life science, Paris University, France.
Professional background: Merck Serono, Chief Medical Officer; Serono, Chief Medical Officer International; various executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron. Head of Global Clinical Development for Actelion 2009-2017. Joined Idorsia as Head of Global Clinical Development when the company was established in June 2017.
Date of birth: June 23 1965
Education: BSc Medical Biochemistry with Honors University of Birmingham, Birmingham, UK
Professional background: From 1995–2012, various marketing and General Manager positions at Glaxosmithkline in the UK, USA, and Denmark; Global President of Stiefel, a GSK company (2012–2014): SVP, Head Global Franchises & Platforms (Pharmaceuticals), GSK (2014–2018).
Date of birth: 30 October 1963
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: From 1994 until 2011, held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as CFO from 2002. CFO of Actelion 2013-2017. Joined Idorsia as CFO when the company was established in June 2017.
The Idorsia Leadership Team
Date of birth: 7 September 1968
Education: Master’s degree in Business Administration, Monetary Economics and Corporate Law from the University of Zurich and Chartered Financial Analyst (CFA).
Professional background: Built a deep expertise and network in the area capital markets, while focusing on gaining an understanding for the pharmaceutical and biotechnology market. Stepping stones as sell-side analyst, buy-side analyst and fund manager include: Equity analyst for European Pharmaceuticals at Warburg Dillon Read (1997–1999) and analyst/ fund manager at Julius Baer (2000–2005). Senior financial analyst covering Swiss/European pharmaceutical/biotechnology stocks for Bank Leu (2005), Bank Sarasin (2006) and Bank Vontobel (2007). Team leader for Life Sciences Equity Research at Bank Vontobel (2008–2014). Head of Investor Relations & Corporate Communications for Actelion 2014-2017. Joined Idorsia as Head of Investor Relations & Corporate Communications when the company was established in June 2017.
Date of birth: 11 September 1978
Education: Master degree in Human Resources Management in Russia, Bachelor degree in Finance in Russia; further education and training in Business Administration and Communication in the US (California State University East Bay, Hayward) and in Coaching and Neuro-linguistic Programming in Erickson College, Vancouver, Canada.
Professional background: HR Manager and Organizational Development Manager at British American Tobacco in Russia and in Switzerland 2003-2007; HR Director for Global Clinical Development and Head of Global Talent Acquisition and Development at Actelion 2007-2017. As of 2013 practicing independent professional coach. Joined Idorsia as Head of Human Resources when the company was established in June 2017.
Date of birth: 20 February 1970
Education: J.D. from the University of Bern, Switzerland. Admission to the Bar of the Canton of Bern.
Professional Background: Legal Counsel for transactions and litigation 2000-2007 in a telecommunications company, 2007-2017 Associate General Counsel and Deputy Group Compliance Officer at Actelion. Joined Idorsia as Group General Counsel when the company was established in June 2017.
Date of birth: 16 December 1966
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd. Joined Idorsia as Head of Pharmaceutical Development when the company was established in June 2017.
Date of birth: 20 June 1954
Education: PhD, organic chemistry at the ETH Zurich, Switzerland with post-doctoral training at Columbia University New York, USA.
Professional background: Research chemist 1983-1986, Group leader 1986-1994, Area head of chemistry in thrombosis/arteriosclerosis research 1994-1999, F. Hoffmann-La Roche Ltd. Head of Drug Discovery, Chemistry, Actelion, 1999–2017. Joined Idorsia as Head of Drug Discovery Chemistry when the company was established in June 2017.
Date of birth: 14 January 1962
Education: Doctoral degree. Dr. Phil.II at the University of Basel, Switzerland, further education at Stanford University, School of Medicine, Stanford, CA, US.
Professional background: Research Scientist, Thrombosis Group at Hoffmann-La Roche, 1994-1997. Project Leader “Novel Oral Anticoagulant Project” at Hoffmann-La Roche, 1997-2002. Head of Biology, Axovan Pharmaceutical, 2002-2003. Senior Group Leader, Immunology/Thrombosis Biology at Actelion Pharmaceuticals Ltd, 2003-2016. Head DD Biology, at Actelion Pharmaceuticals Ltd, 2016-2017. Joined Idorsia as Head of Drug Discovery Biology when the company was established in June 2017.
Date of birth: 1 April 1967
Education: PhD in Biochemistry/Life Sciences, Universities of Kaiserslautern and Frankfurt, Msc Toxicology, University of Surrey, UK
Professional background: From 1993 until 2004, various positions in project toxicology/drug development at Sandoz, Ciba and F. Hoffmann-La Roche, 2004-2017 Head of Toxicology, Actelion, since 2011 Head of Preclinical Development, Actelion. Joined Idorsia as Head of Drug Discovery Pharmacology & Preclinical Development when the company was established in June 2017.